Meeting
2016 ASCO Annual Meeting
Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).
Authors
Carmine De Angelis
Baylor College of Medicine, Houston, TX
Carmine De Angelis , Chandandeep Nagi , Cliff Hoyt , Liu Linying , Kristin Roman , Chichung Wang , Yi Zheng , Tao Wang , Rena Mao , Susan G. Hilsenbeck , Carolina Gutierrez , Antonio C. Wolff , C. Kent Osborne , Mothaffar F. Rimawi , Rachel Schiff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 608)
DOI
10.1200/JCO.2016.34.15_suppl.608
Abstract #
608
Poster Bd #
96
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao
Poster
2018 ASCO Annual Meeting
A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).
First Author: Emanuela Risi
Poster
2015 ASCO Annual Meeting
Effect of tumor infiltrating lymphocytes (TILs) and stromal CD68 on trastuzumab (T) benefit in early stage HER2 positive breast cancer (BC).
First Author: Jacques Raphael